MX2010009487A - Antagonistas de tipo 3-aminoalquil-1,4-diazepam-2-ona del receptor de melanocortina-5. - Google Patents

Antagonistas de tipo 3-aminoalquil-1,4-diazepam-2-ona del receptor de melanocortina-5.

Info

Publication number
MX2010009487A
MX2010009487A MX2010009487A MX2010009487A MX2010009487A MX 2010009487 A MX2010009487 A MX 2010009487A MX 2010009487 A MX2010009487 A MX 2010009487A MX 2010009487 A MX2010009487 A MX 2010009487A MX 2010009487 A MX2010009487 A MX 2010009487A
Authority
MX
Mexico
Prior art keywords
melanocortin
diazepan
aminoalkyl
receptor antagonists
diseases
Prior art date
Application number
MX2010009487A
Other languages
English (en)
Inventor
Arnold Thomas Blaskovich Mark
Joseph Cassidy Peter
Original Assignee
Mimetica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetica Pty Ltd filed Critical Mimetica Pty Ltd
Publication of MX2010009487A publication Critical patent/MX2010009487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) que son útiles para modular la actividad biológica del receptor de melanocortina 5 (MC5R). Los compuestos de esta invención se pueden emplear para tratar enfermedades y/o afecciones en las que la reducción de MC5R es beneficiosa. Estas enfermedades y/o afecciones incluyen, pero no se limitan a, acné, seborrea, dermatitis seborreica, cáncer y enfermedades inflamatorias.
MX2010009487A 2008-02-29 2009-02-27 Antagonistas de tipo 3-aminoalquil-1,4-diazepam-2-ona del receptor de melanocortina-5. MX2010009487A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3289408P 2008-02-29 2008-02-29
US12/391,720 US8008291B2 (en) 2008-02-29 2009-02-24 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
PCT/AU2009/000230 WO2009105823A1 (en) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2010009487A true MX2010009487A (es) 2011-03-02

Family

ID=41015440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009487A MX2010009487A (es) 2008-02-29 2009-02-27 Antagonistas de tipo 3-aminoalquil-1,4-diazepam-2-ona del receptor de melanocortina-5.

Country Status (17)

Country Link
US (1) US8008291B2 (es)
EP (1) EP2257534B1 (es)
JP (1) JP5503557B2 (es)
KR (1) KR101620114B1 (es)
CN (1) CN102007105B (es)
AU (1) AU2009219106B2 (es)
BR (1) BRPI0907903B1 (es)
CA (1) CA2716250C (es)
DK (1) DK2257534T3 (es)
ES (1) ES2445456T3 (es)
HK (1) HK1148730A1 (es)
IL (1) IL207700A (es)
MX (1) MX2010009487A (es)
NZ (1) NZ587363A (es)
PT (1) PT2257534E (es)
RU (1) RU2530017C2 (es)
WO (1) WO2009105823A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907906A2 (pt) * 2008-02-29 2020-08-18 Mimetica Pty Ltd composto e uso do mesmo no tratamento de condições relacionadas com receptor mc5
US20120141392A1 (en) * 2009-02-27 2012-06-07 Mimetica Pty Ltd Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途
CN115381955B (zh) * 2021-05-24 2024-05-17 中国科学技术大学 黑皮质素受体mc5r的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ254752A (en) 1992-08-21 1997-06-24 Wa Pharma Ab Dna fragments encoding melanocyte stimulating hormone receptors, their use in production of encoded polypeptides and diagnostic and therapeutic methods
US5622860A (en) 1994-02-17 1997-04-22 The Regents Of The University Of Michigan Genes encoding melanocortin receptors
WO1996022304A1 (en) 1995-01-20 1996-07-25 Molecumetics, Ltd. Conformationally constrained reverse-turn library and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO1998049186A1 (en) 1997-04-25 1998-11-05 The Regents Of The University Of California Dipeptide surrogates containing asparagine-derived tetrahydropyrimidinones
AUPP254898A0 (en) 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
AU742747B2 (en) 1998-03-24 2002-01-10 Mimetica Pty Ltd Peptide turn mimetics
WO2000028002A1 (en) 1998-11-09 2000-05-18 Merck & Co., Inc. Dna molecules encoding the melanocortin 5 receptor protein from rhesus monkey
CN1178922C (zh) * 2000-05-25 2004-12-08 弗·哈夫曼-拉罗切有限公司 取代的1-氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US20030110518A1 (en) 2001-09-28 2003-06-12 Houseknecht Karen L. Melanocortin-5 receptor sequences and uses thereof
US6916812B2 (en) * 2001-10-09 2005-07-12 Bristol-Myers Squibb Company Alpha-aminoamide derivatives as melanocortin agonists
PT1446394E (pt) 2001-11-08 2007-01-31 Ortho Mcneil Pharm Inc Novos derivados de 1,2,4-tiadiazole como moduladores do receptor da melanocortina
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
RU2006101541A (ru) 2003-06-20 2006-06-10 Амген Инк. (US) Производные пиперазина и способ их применения
US7281642B2 (en) * 2004-09-16 2007-10-16 Prime Time Toys, Ltd. Squirting toy
WO2008017852A1 (en) 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators
BRPI0907906A2 (pt) * 2008-02-29 2020-08-18 Mimetica Pty Ltd composto e uso do mesmo no tratamento de condições relacionadas com receptor mc5

Also Published As

Publication number Publication date
RU2530017C2 (ru) 2014-10-10
NZ587363A (en) 2012-06-29
KR20100122102A (ko) 2010-11-19
KR101620114B1 (ko) 2016-05-12
IL207700A0 (en) 2010-12-30
RU2010137034A (ru) 2012-04-10
HK1148730A1 (es) 2011-09-16
ES2445456T3 (es) 2014-03-03
IL207700A (en) 2017-01-31
US20090221557A1 (en) 2009-09-03
AU2009219106A1 (en) 2009-09-03
EP2257534B1 (en) 2013-11-06
DK2257534T3 (da) 2014-02-03
JP2011513244A (ja) 2011-04-28
AU2009219106B2 (en) 2013-09-26
JP5503557B2 (ja) 2014-05-28
WO2009105823A1 (en) 2009-09-03
US8008291B2 (en) 2011-08-30
CN102007105B (zh) 2014-09-03
PT2257534E (pt) 2014-02-17
CN102007105A (zh) 2011-04-06
BRPI0907903B1 (pt) 2021-11-09
EP2257534A1 (en) 2010-12-08
CA2716250C (en) 2016-02-16
EP2257534A4 (en) 2011-05-04
CA2716250A1 (en) 2009-09-03
BRPI0907903A2 (pt) 2020-08-18

Similar Documents

Publication Publication Date Title
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
IN2014KN02601A (es)
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
TN2011000627A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
MY175979A (en) Certain chemical entities, compositions and methods
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX2012002066A (es) Compuestos heterociclicos y usos de los mismos.
JO3131B1 (ar) مركبات كيميائية
EA019744B9 (ru) Изотиазолилоксифениламидины и их применение для борьбы с фитопатогенными грибами и семенной материал, обработанный изотиазолилоксифениламидинами
UA99839C2 (ru) Бензодиазепиноновые соединения, применяемые при лечении кожных состояний
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2010009488A (es) Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor.
MY186456A (en) Quinazoline carboxamide azetidines
IN2012DN02471A (es)
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
MY150600A (en) Use of opioid antagonists for treating urinary retention
AU2012357747A8 (en) TRPM8 antagonists
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
MX2010009487A (es) Antagonistas de tipo 3-aminoalquil-1,4-diazepam-2-ona del receptor de melanocortina-5.

Legal Events

Date Code Title Description
FG Grant or registration